ProShare Advisors
TNGX icon

ProShare Advisors’s Tango Therapeutics TNGX Stock Holding History

ProShare Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$463K Sell
22,124
-3,260
-13% -$45.4K ﹤0.01% 1107
2025
Q4 		$225K Buy
25,384
+9,154
+56% +$78.9K ﹤0.01% 1642
2025
Q3 		$136K Sell
16,230
-3,545
-18% -$24K ﹤0.01% 1783
2025
Q2 		$101K Buy
19,775
+4,570
+30% +$11.3K ﹤0.01% 1875
2025
Q1 		$20.8K Sell
15,205
-3,319
-18% -$8.15K ﹤0.01% 2035
2024
Q4 		$57.2K Buy
18,524
+3,178
+21% +$14.8K ﹤0.01% 2162
2024
Q3 		$118K Buy
15,346
+2,772
+22% +$26.5K ﹤0.01% 1852
2024
Q2 		$108K Sell
12,574
-2,595
-17% -$20.1K ﹤0.01% 1654
2024
Q1 		$120K Buy
15,169
+1,263
+9% +$13.5K ﹤0.01% 1788
2023
Q4 		$138K Buy
13,906
+2,324
+20% +$20.2K ﹤0.01% 1728
2023
Q3 		$130K Buy
11,582
+56
+0.5% +$341 ﹤0.01% 1582
2023
Q2 		$38.3K Sell
11,526
-76
-0.7% -$273 ﹤0.01% 1796
2023
Q1 		$45.8K Sell
11,602
-1,691
-13% -$9.81K ﹤0.01% 1681
2022
Q4 		$96.4K Buy
+13,293
New +$93.5K ﹤0.01% 1657

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

ProShare Advisors's TNGX Position: Q1 2026 in Review

ProShare Advisors reduced its Tango Therapeutics (TNGX) stake by 13% in Q1 2026, selling an estimated $45.4K and leaving 22,124 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

ProShare Advisors first reported a position in TNGX in Q4 2022 and has held it in 14 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • ProShare Advisors held 22,124 shares of Tango Therapeutics worth $463K as of Q1 2026.
  • ProShare Advisors sold 3,260 Tango Therapeutics shares in Q1 2026, an estimated $45.4K.
  • Tango Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1107 holding.
  • ProShare Advisors first reported a position in Tango Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.